Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece una nueva terapia para el tratamiento de la degeneración macular asociada con la edad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20170914001
Publicado:
13/10/2017
Caducidad:
13/10/2018
Resumen:
Una oficina francesa de transferencia de tecnología ofrece una nueva estrategia terapéutica para el tratamiento de la degeneración macular asociada con la edad. La oficina ha demostrado que la inhibición de IL-6 permite controlar la inflamación subretiniana patológica y prevenir la degeneración del fotorreceptor. Las ventajas de los anticuerpos anti-IL-6 han sido destacadas en ratones. La oficina está interesada en desarrollar el tratamiento desde la fase in vitro hasta la fase in vivo mediante acuerdos de licencia o cooperación en materia de investigación.

Details

Tittle:
French Technology Transfer Office offers a new therapeutic to treat dry Age related Macular Degeneration
Summary:
The French TTO (Technology Transfer Office) offers a new therapeutic strategy to treat dry Age related Macular Degeneration (dry AMD). They demonstrated that the inhibition of IL-6 could be used to control pathologic subretinal inflammation and prevent the photoreceptor degeneration.
It is proposed to develop the therapeutic from in vitro stage to in vivo stage, through licence agreement or research cooperation agreement.
Description:
The French TTO (Technology Transfer Office) is acting on behalf of an established public laboratory of a university of the Paris region.

The French public laboratory has developed a new therapeutic strategy to treat Age related macular degeneration (AMD).
AMD is a progressive illness, which is the most common cause of blindness in developed countries. The number of people living with AMD is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040.

AMD is associated with a breakdown of the subretinal immunosuppressive environment and chronic accumulation of mononuclear phagocytes (MPs).There are two basic types of macular degeneration: "dry" and "wet". Approximately 85% to 90% of the cases of macular degeneration are the "dry" (atrophic) type.

As no treatment of dry AMD has yet reached the market this new therapeutic strategy developed from the understanding of the inflammation process involved in dry AMD, makes IL-6 (InterLeukins-6 are small pro-inflammatory proteins) a key target.

French laboratory demonstrated that the inhibition of IL-6 could be used to control pathologic subretinal inflammation and prevent the photoreceptor degeneration.

It is proposed to develop the therapeutic from in vitro stage to in vivo stage. Indeed, the benefit of anti-IL-6 antibodies was highlighted in mice.
The french TTO is looking for a company that will licence the patent or sign a research cooperation agreement in order to go through clinical phases and develop a treatment for dry AMD and Retinitis pigmentosa.

Keywords : #eye disease #ophthalmology #vision #retina #macula #drusen
Advantages and Innovations:
As no treatment of dry AMD has yet reached the market and very few candidates are in clinical development, this new therapeutic strategy developed from the understanding of the inflammation process involved in dry AMD, makes IL-6 a key target.
Suggested applications :
· Prevention and treatment of dry AMD
· Prevention and treatment of retinitis pigmentosa
Stage of Development:
Available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Priority patent application filed in 2014. The innovation is protected in the following countries : Europe, Brazil, Russia, USA, South-Korea, Australia, Mexico, Japan, Israel, Canada and China.

Partner sought

Type and Role of Partner Sought:
The TTO is looking for a company that will licence the patent or sign a research cooperation agreement in order to go through clinical phases and develop a treatment for dry AMD and Retinitis pigmentosa.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001015 Productos farmacéuticos / medicamentos